GBA Presents: THE GREEN MARKET

Possible Short- EXPD

Morgan Stanley cuts Expeditors to Underweight amid industry downgrade 07:17 EXPD Morgan Stanley analyst Ravi Shanker is lowering his Freight Transportation industry view from In-Line to Cautious and has downgraded Expeditors to Underweight from Equal Weight with a price target of $95, down from $110. The transportation cycle is "probably closer to the end than the middle," contends Shanker, who thinks 2022 is likely to see momentum continue into the first half but then he does not see significant upside to the cycle from there barring another outbreak of the pandemic causing new disruptions or major weather events. Shanker expects inventory levels at shippers to normalize by mid-2022, by which time supply chain congestion should also see relief, leading to a weaker second half of the year for the sector, the analyst explains.
 
Canada Goose employees vote to unionize in Winnipeg, NYT reports 06:09 GOOS Employees at three facilities owned by Canada Goose in Winnipeg, Manitoba have overwhelmingly voted to unionize, the New York Times' Noam Scheiber reports, citing the results. Workers United will represent roughly 1,200 additional workers as a result of the election, which had about 86% of those voting supporting unionization.

GOOS
15.38K followersCanada Goose Holdings Inc.
41.28
-3.31(-7.42%)
4:00 PM 12/01/21
Pre-Market:$40.93-0.35(-0.85%)


Sasol upgraded to Overweight from Neutral at JPMorgan 06:08 SSL JPMorgan analyst Alex Comer upgraded Sasol to Overweight from Neutral.

SASOF
Sasol Limited
15.60
0.79(+5.36%)

Farfetch assumed with a Buy at UBS 05:15 FTCH UBS analyst Kunal Madhukar assumed coverage of Farfetch with a Buy rating and $45 price target. The analyst is bullish on the Farfetch Platform Solutions suite of solutions and notes that Richemont said "Farfetch is seen as having the best technology in the market, which cannot be replicated." The company could benefit from "several exciting trends," including the overall transition to onlineand the shift in spend to Mainland China, Madhukar tells investors in a research note.

FTCH
Farfetch Limited
34.02
-0.39(-1.13%)
4:00 PM 12/01/21
Pre-Market:$34.77+0.75(+2.21%)


Qiagen receives CE mark for QuantiFERON SARS-CoV-2 assay 05:17 QGEN Qiagen announced the CE marking of its QuantiFERON SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.

QGEN
QIAGEN N.V.
54.21
-0.92(-1.67%)
4:00 PM 12/01/21
Pre-Market:$54.70+0.49(+0.90%)8:11 AM
 
NO!

I know what you are trying to do Van absolutely not!

Yullia does not need these.

Company Overview
Establishment Labs Holdings (ESTA)is a Costa Rican-based medical technology company that IPO’d in 2018. The firm is focused on women’s health, currently developing products for the breast aesthetics and reconstruction market. The company has a portfolio of silicone gel-filled breast implants that go by brand name Motiva Implants. In addition to the implant products, the company’s portfolio consists of the Divina 3D Simulation System and other products and services. Establishment Labs Holdings has a market capitalization of roughly $440 million and trades for around $18.50 a share.

Pipeline:

 

...
The big news of late was the announcement in early August that the firm has entered into a definitive agreement with their Italian distributor to transition to a direct sales force in that market. Italy is the fifth largest country in the world for breast augmentation procedures, and the transition to direct sales is seen as a key move in order to generate long-term profitable growth. The company has already established a direct sales presence in France, Germany, Spain, the United Kingdom and several additional countries.
 
stonedinvestor said:
Agreed.

Been waiting for these numbers---


C3 AI Announces Second Quarter Fiscal 2022 Results
bc7582eae4bb21389ed9650a30f93a19

Wed, December 1, 2021, 4:20 PM
In this article:

Q2 Revenue of $58.3 million, increased 41% year over year

FY 22 Revenue Guidance raised to 35% - 37% growth, up from 17% growth in FY 21

TIME TO BUY VAN-?

REDWOOD CITY, Calif., December 01, 2021--(BUSINESS WIRE)--C3.ai, Inc. (NYSE: AI), the Enterprise AI software company, today announced results for its fiscal second quarter ended October 31, 2021.

"We closed another strong quarter, including a revenue increase of 41% from a year ago that exceeds our guidance and sell-side analysts’ expectations," said CEO Thomas M. Siebel. "We expanded our important relationship with Baker Hughes extending the contract term, significantly increasing its value, and securing that value as a guaranteed future C3 AI revenue stream. We further diversified our enterprise AI production footprint across many industries and continued to innovate with the delivery of C3 AI Data Vision, that fundamentally reinvents the enterprise software user experience."

Second Quarter Financial Highlights

  • Revenue: Total revenue for the quarter was $58.3 million, up from $41.3 million one year ago, an increase of 41% year over year, exceeding company guidance and sell-side analysts’ expectations.

  • Subscription Revenue: Subscription revenue for the quarter was $47.4 million, up from $35.9 million one year ago, an increase of 32% year over year.

  • Gross Profit: GAAP Gross profit for the quarter was $42.3 million, up from $31.3 million one year ago. Non-GAAP gross profit for the quarter was $45.3 million, up from $31.5 million one year ago, exceeding sell-side analysts’ consensus expectations by $1.6 million.

  • Remaining Performance Obligations ("RPO"): GAAP RPO was $465.5 million, up from $267.4 million one year ago. Non-GAAP RPO was $529.3 million, up from $304.5 million one year ago.

  • Net Loss per Share: GAAP net loss per share was $(0.55), compared to $(0.39) one year ago. Non-GAAP net loss per share was $(0.23), compared to $(0.26) one year ago, well above sell-side analysts' consensus expectations.
More...
yikes!
$28
 
Alright one emergency into another. I am back from the vet total success! Got two shots, a year of blood work and his anal glands drained one had blood & infection.

Get home take a breath and my kid emails me a picture of his finger and he has three or four I don't know blisters warts,... flea bites, Spider bite... allergy.... I'm thinking of all good things...

ATAI INCREASES OWNERSHIP IN COMPASS:Atai Life Sciences (ATAI)announced Mondaythat it has increased its ownership interest in COMPASS Pathways (CMPS) from 19.4% to 20.8%. The company said, “This equity stake increase is a demonstration of atai’s confidence in COMPASS Pathways and in the potential of COMP360 in mental health care, following the recent COMP360 data in treatment-resistant depression. This solidifies atai’s position as COMPASS’ largest shareholder.”

Following the news,Maxim analystMichael Okunewitch initiated coverage of Atai Life Sciences with a Buy rating and $25 price target. The analyst said he is positive on the company's pipeline of novel and "de-risked assets" in mental health and central nervous system disease, with compounds targeting treatment-resistant depression, substance use disorder, anxiety, post-traumatic stress disorder, cognitive effects of schizophrenia, and mild traumatic brain injury. Atai's strategy of selecting compounds with prior evidence in humans in areas of high unmet need has established it as not just a leader in psychedelics, but CNS disease more broadly, Okunewitch said.

C3.ai downgraded to Underperform at BofA after 'disappointing' Q2 report 09:05 AI, GOOGL, GOOG, MSFT BofA analyst Brad Sills downgraded C3.ai (AI) to Underperform from Neutral with a price target of $40, down from $65, following what he called a "disappointing" Q2 report that featured lighter than expected subscription revenue and a sequential decline in Remaining Performance Obligations, or RPO, excluding the impact from the Baker Hughes (BKR) agreement reallocation from cancellable to non-cancellable RPO. He is encouraged by the move to non-cancellable RPO, which should provide some revenue visibility, as well as the commentary suggesting meaningful pipeline builds for joint solutions with Google (GOOGL) and Microsoft (MSFT), but thinks that near-term uncertainty introduced by execution challenges and the departure of CFO David Barter are likely to be an overhang on the shares, Sills said.


DLTH
Duluth Holdings<----- Is this the underwear company?
$15.12
+1.53(+11.26%)
 
vanzandt said:
yikes!
$28
More...



Looking Good Van! I'm tempted to plant right now what do you think.-?
This is our 2022 pick so we can buy it any time from now until the new year...


C3.ai, Inc. (AI)
NYSE - Nasdaq Real Time Price. Currency in USD

28.47-5.36(-15.83%) :confused:
As of 10:59AM EST.

 
You must log in or register to reply here.
Back
Top